---
title: "Citi Keeps Their Hold Rating on Amgen (AMGN)"
description: "According to TipRanks, Meacham is a 4-star analyst with an average return of 4.2% and a 55.14% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260882086.md"
published_at: "2025-10-13T10:55:50.000Z"
---

# Citi Keeps Their Hold Rating on Amgen (AMGN)

> According to TipRanks, Meacham is a 4-star analyst with an average return of 4.2% and a 55.14% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals. In addition to Citi, Amgen also received a Hold from Raymond James’s Christopher Raymond in a report issued on October 10. However, on October 8, RBC Capital maintained a Buy rating on Amgen (NASDAQ: AMGN).

According to TipRanks, Meacham is a 4-star analyst with an average return of 4.2% and a 55.14% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals.

In addition to Citi, Amgen also received a Hold from Raymond James’s Christopher Raymond in a report issued on October 10. However, on October 8, RBC Capital maintained a Buy rating on Amgen (NASDAQ: AMGN).

### Related Stocks

- [AMGN.US - Amgen](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 福泰製藥｜8-K：2025 財年 Q4 營收 31.9 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275807197.md) |
| 安進｜8-K：2025 財年 Q4 營收 98.66 億美元超過預期 |  | [Link](https://longbridge.com/en/news/274709467.md) |
| 對安進 2025 年第四季度財報的預期 | 安進 2025 年第四季度財報的預期 | [Link](https://longbridge.com/en/news/271647537.md) |
| Vanda 製藥｜10-K：2025 財年營收 2.16 億美元不及預期 |  | [Link](https://longbridge.com/en/news/275753219.md) |
| 安進（AMGN）憑藉強勁的業績和管線動能推動 2025 年的股價上漲 | 安進（Amgen Inc.，NASDAQ:AMGN）被評選為 2026 年 14 只最佳製藥股息股票之一。該公司展現了強勁的財務表現和持續的臨牀進展，儘管面臨即將到來的專利到期的擔憂，今年股票價值仍增長了 27% | [Link](https://longbridge.com/en/news/271148065.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.